Inactive Instrument

Press Releases Bellerophon Therapeutics LLC Nasdaq

Equities

End-of-day quote Nasdaq Other stock markets
-	-

05-02	North American Morning Briefing : Stock Futures -2-	DJ
04-25	North American Morning Briefing : More Tech -2-	DJ

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Bellerophon Therapeutics : Costs Associated with Exit/Disposal - Form 8-K	29/06/23	PU
Bellerophon Therapeutics : Conference Call Presentation	05/06/23	PU
Bellerophon Announces Top-Line Data from Phase 3 REBUILD Clinical Trial of INOpulse® for Treatment of Fibrotic Interstitial Lung Disease	05/06/23	AQ
Bellerophon Therapeutics : Corporate Presentation	22/05/23	PU
BELLEROPHON THERAPEUTICS, INC. : Results of Operations and Financial Condition, Financial Statements and Exhibits (form 8-K)	15/05/23	AQ
Bellerophon Therapeutics: Q1 Earnings Snapshot	15/05/23	AQ
Bellerophon Provides Clinical Program Update and Reports First Quarter 2023 Financial Results	15/05/23	AQ
Bellerophon Therapeutics Announces Last Patient Has Completed Blinded Treatment in Phase 3 REBUILD Study for INOpulse in Fibrotic Interstitial Lung Disease	12/05/23	AQ
BELLEROPHON THERAPEUTICS, INC. : Change in Directors or Principal Officers (form 8-K)	11/05/23	AQ
BELLEROPHON THERAPEUTICS, INC. : Other Events, Financial Statements and Exhibits (form 8-K)	11/05/23	AQ
Bellerophon Therapeutics Announces Last Patient Has Completed Blinded Treatment in Phase 3 REBUILD Study for INOpulse® in Fibrotic Interstitial Lung Disease	11/05/23	AQ
BELLEROPHON THERAPEUTICS, INC. : Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K)	05/05/23	AQ
BELLEROPHON THERAPEUTICS, INC. : Change in Directors or Principal Officers (form 8-K)	25/04/23	AQ
BELLEROPHON THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-K)	31/03/23	AQ
Bellerophon Therapeutics : Strengthened Balance Sheet Through $5 Million Registered Direct Offering with Life Sciences-focused Institutional Investor - Form 8-K	31/03/23	PU
Bellerophon Provides Clinical Program Update and Reports Full-Year 2022 Financial Results	31/03/23	AQ
Bellerophon Therapeutics : Material Agreement - Form 8-K	06/03/23	PU
BELLEROPHON THERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Financial Statements and Exhibits (form 8-K)	06/03/23	AQ
Bellerophon Therapeutics Announces $5 Million Registered Direct Offering	06/03/23	AQ
BELLEROPHON THERAPEUTICS, INC. : Other Events (form 8-K)	03/03/23	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Bellerophon Therapeutics LLC Nasdaq

Equities

Press Releases

Filters